Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.

European journal of cancer (Oxford, England : 1990) - 1 Oct 2017

Nebot-Bral Laetitia, Brandao David, Verlingue Loic, Rouleau Etienne, Caron Olivier, Despras Emmanuelle, El-Dakdouki Yolla, Champiat Stéphane, Aoufouchi Said, Leary Alexandra, Marabelle Aurélien, Malka David, Chaput Nathalie, Kannouche Patricia L

Abstract excerpt

Immune checkpoint inhibitors have demonstrated unprecedented clinical activity in a wide range of cancers. Significant therapeutic responses have recently been observed in patients presenting mismatch repair-deficient (MMRD) tumours. MMRD cancers exhibit a remarkably high rate of mutations, which can result in the formation of neoantigens, hypothesised to enhance the antitumour immune response. In addition to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to DNA Mismatch Repair

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Polymerase II

Share to DNA Polymerase III

Share to Immunotherapy

Share to Microsatellite Instability

Share to Poly-ADP-Ribose Binding Proteins

Share to Tumor Escape

Source

Identifiers

PMID: 28846956
DOI: 10.1016/j.ejca.2017.07.026

Genes

POLE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.PMID 28846956Read ↗

Polymerase Epsilon-Associated Ultramutagenesis in CancerSemantic proximity Read ↗

Hypermutated Tumors and Immune Checkpoint Inhibition.Semantic proximity Read ↗

The Clinical Impact of the Genomic Landscape of Mismatch Repair–Deficient CancersSemantic proximity Read ↗

Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumorsSemantic proximity Read ↗

The game-changing impact of POLE mutations in oncology—a review from a gynecologic oncology perspectiveSemantic proximity Read ↗

POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapySemantic proximity Read ↗

Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.Semantic proximity Read ↗

POLE/POLD1 mutation and tumor immunotherapy.Semantic proximity Read ↗

Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator SyndromesSemantic proximity Read ↗

Immune Checkpoint Blockade Delays Cancer and Extends Survival in Murine DNA Polymerase Mutator SyndromesSemantic proximity Read ↗

Immune checkpoint inhibitors in POLE/POLD1 proofreading-deficient CRC: from molecular basis to clinical practice and future directions.Semantic proximity Read ↗

Hypermutation and microsatellite instability in gastrointestinal cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.